title: [Early and late nosocomial broncho-pulmonary diseases in intensive care. Comparative study of risk factors and of causing bacteria].
abstract: OBJECTIVE
  Determine the risk factors and germs responsible for early-onset (E) and late-onset (L) nosocomial broncho-pulmonary infections (NBPI), in order to improve preventive strategies and the choice of initial antibiotherapy.
  
  
  METHODS
  An observational prospective study conducted in an intensive care unit of 30 beds, from March 1993 to September 1999. The patients presenting with an ENBPI and those with an LNBPI were compared with patients without NBPI using univariate and then multivariate analysis.
  
  
  RESULTS
  517 (14%) of early-onset NBPI were diagnosed, but the majority of NBPI were late-onset (87%). Multiresistant bacteria predominated. The similarity in the germs responsible for the early and late onset forms of NBPI was probably related to the large number of patients transferred from other departments (82%) and having already received antibiotics before their admission to the intensive care unit (49%). Multivariate analysis identified anti-ulcer and long term corticosteroid treatments as common risk factors for early and late onset forms of NBPI, digestive failure, tracheotomy and kidney failure as risk factors for ENBPI and the number of antibiotics used in intensive care and the duration of mechanical ventilation as factors of risk for LNBPI.
  
  
  CONCLUSIONS
  The limited use of antibiotics and anti-ulcer agents could improve the prevention of early and late onset forms of NBPI. The distinction in intensive care between the two forms of NBPI must be emphasized by the notion of prior hospitalization.
authors.affiliation: Hôpital Calmette, CHRU, Bd du Pr Leclercq, 59037 Lille. s-nseir@chru-lille.fr
authors.forename: S
authors.initials: S
authors.lastname: Nseir
authors.forename: C
authors.initials: C
authors.lastname: Di Pompéo
authors.forename: P
authors.initials: P
authors.lastname: Pronnier
authors.forename: S
authors.initials: S
authors.lastname: Soubrier
authors.forename: T
authors.initials: T
authors.lastname: Onimus
authors.forename: F
authors.initials: F
authors.lastname: Saulnier
authors.forename: B
authors.initials: B
authors.lastname: Grandbastien
authors.forename: M
authors.initials: M
authors.lastname: Roussel-Delvallez
authors.forename: D
authors.initials: D
authors.lastname: Mathieu
authors.forename: A
authors.initials: A
authors.lastname: Durocher
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001982:Bronchial Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D018432:Drug Resistance, Multiple; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D008171:Lung Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents